© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#Mylan

Only Subnormal Kidney Function May Get Boost From Switch to New Tenofovir

Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.

44 States Sue 20 Makers of Generic Drugs Over Alleged Price Fixing

At the center of the lawsuit is Teva Pharmaceutical, slated to sell a generic version of the HIV prevention pill PrEP next year.

Older Tenofovir May Not Be Tied to Fracture Risk After All

Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.

Cut-Price HIV Meds

The FDA approves three new, cheaper combination ARV tablets.
Gilead’s float in the Seattle LGBT pride parade, June 2017

Is Gilead’s Entire HIV Enterprise Built on a False Promise?

A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.

FDA OKs Symfi, Mylan’s Third Cut-Price Single-Tablet HIV Regimen

The tablet contains the same combo as Symfi Lo (efavirenz/lamivudine/tenofovir disoproxil fumarate) but with a higher dose of efavirenz.

FDA Approves Mylan’s Cut-Price HIV Tablets Symfi Lo and Cimduo

Symfi Lo contains efavirenz, lamivudine and tenofovir disoproxil fumarate (TDF); Cimduo contains TDF and lamivudine.
Advertisement